Small cell lung cancer
Conditions
Interventions
Small cell lung Cancer Observation group:None
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients must meet all the following inclusion criteria to be eligible for this trial: 1. Age between 18 and 75 years old; 2. Patients with ES-SCLC confirmed by pathology through imaging and tumor biopsy; 3. Complete previous pathological information and clinical follow-up information of the patient; 4. Ability to obtain sufficient pre-treatment tumor tissue samples and pre-treatment/post-treatment blood ctDNA for 425-panel sequencing and PD-L1 protein expression detection, and the patient can provide peripheral blood samples as negative controls; 5. The patient's subsequent treatment is planned to use an immunotherapy regimen; 6. The patient's other indicators meet the general inclusion criteria for clinical trials; 7. The participant voluntarily joins this study, signs the informed consent form, has good compliance, and cooperates with follow-up.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1. Patients who are not planned to receive an immunotherapy regimen; 2. Patients who, for various reasons, are unable to obtain pre-treatment tumor tissue samples, pre-treatment and post-treatment plasma ctDNA, and whole blood negative control samples. 3. Patients who are unable to obtain follow-up information; 4. Individuals whom the investigator deems unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between Baseline ctDNA Levels with Patient Immunotherapy Efficacy and Prognosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival ;Overall Survival;Objective Response Rate ;Disease Control Rate ; | — |
Countries
China
Contacts
Public ContactQin Jing
Zhejiang Cancer Hospital
Outcome results
None listed